1. Home
  2. XFOR vs ECF Comparison

XFOR vs ECF Comparison

Compare XFOR & ECF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XFOR
  • ECF
  • Stock Information
  • Founded
  • XFOR 2014
  • ECF 1986
  • Country
  • XFOR United States
  • ECF United States
  • Employees
  • XFOR N/A
  • ECF N/A
  • Industry
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • ECF Finance/Investors Services
  • Sector
  • XFOR Health Care
  • ECF Finance
  • Exchange
  • XFOR Nasdaq
  • ECF Nasdaq
  • Market Cap
  • XFOR 118.4M
  • ECF 141.8M
  • IPO Year
  • XFOR N/A
  • ECF N/A
  • Fundamental
  • Price
  • XFOR $1.61
  • ECF $10.47
  • Analyst Decision
  • XFOR Strong Buy
  • ECF
  • Analyst Count
  • XFOR 3
  • ECF 0
  • Target Price
  • XFOR $72.33
  • ECF N/A
  • AVG Volume (30 Days)
  • XFOR 1.8M
  • ECF 57.7K
  • Earning Date
  • XFOR 08-11-2025
  • ECF 01-01-0001
  • Dividend Yield
  • XFOR N/A
  • ECF 6.42%
  • EPS Growth
  • XFOR N/A
  • ECF N/A
  • EPS
  • XFOR 2.16
  • ECF 0.46
  • Revenue
  • XFOR $31,364,000.00
  • ECF N/A
  • Revenue This Year
  • XFOR $1,300.08
  • ECF N/A
  • Revenue Next Year
  • XFOR N/A
  • ECF N/A
  • P/E Ratio
  • XFOR $0.74
  • ECF $17.61
  • Revenue Growth
  • XFOR N/A
  • ECF N/A
  • 52 Week Low
  • XFOR $1.38
  • ECF $7.02
  • 52 Week High
  • XFOR $26.83
  • ECF $8.91
  • Technical
  • Relative Strength Index (RSI)
  • XFOR 40.77
  • ECF 53.92
  • Support Level
  • XFOR $1.55
  • ECF $10.33
  • Resistance Level
  • XFOR $2.22
  • ECF $10.65
  • Average True Range (ATR)
  • XFOR 0.20
  • ECF 0.10
  • MACD
  • XFOR 0.06
  • ECF -0.03
  • Stochastic Oscillator
  • XFOR 26.44
  • ECF 36.49

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

About ECF Ellsworth Growth and Income Fund Ltd.

Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.

Share on Social Networks: